ArticleScientific reports2026
Preoperative lung immune prognostic index (LIPI) predicts postoperative outcomes in clear cell renal cell carcinoma: a multicenter study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06775574 (Prognostic Significance of the Lung Immune Prognostic Index), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carcinoma: a Multicenter Retrospective Cohort Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Lactate dehydrogenase (LDH) and derived neutrophil-to-lymphocyte ratio (dNLR) are key prognostic factors for renal cancer. However, the association between the Lung Immune Prognostic Index (LIPI), based on dNLR and LDH, and renal cancer prognosis remains unclear. This study evaluates the prognostic value of LIPI for recurrence and survival in clear cell renal cell carcinoma (ccRCC) after nephrectomy. This retrospective study included 687 ccRCC patients who underwent radical or partial nephrectomy at three medical centers. Patients were stratified into good and intermediate/poor (int./poor) LIPI groups based on dNLR and LDH. Propensity score matching (PSM) was performed. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using Kaplan-Meier curves and Cox models. Model discrimination was evaluated using C-indices, and subgroup and center-stratified analyses tested robustness. A total of 687 patients were included, with 491 classified into the good LIPI group and 196 into the int./poor group. After 1:1 PSM, each group comprised 196 patients. In the Kaplan-Meier survival analysis, the int./poor LIPI group exhibited significantly worse RFS and OS both before (RFS: P < 0.001; OS: P < 0.001) and after PSM (RFS: P < 0.001; OS: P < 0.001). In the multivariate Cox regression analysis post-PSM, int./poor LIPI remained independently associated with increased risk of recurrence (HR = 2.156, 95% CI: 1.349-3.449, P = 0.001) and mortality (HR = 3.238, 95% CI: 1.437-7.298, P = 0.005). Preoperative LIPI predicts ccRCC prognosis after nephrectomy. Patients in the good LIPI group exhibit significantly better RFS and OS.Trial registration: The study was registered at ClinicalTrials.gov (NCT06775574).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.